Physician profile
David Howard
NPI 1972507838
$607.43
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $271 · 2022: $53.22.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $124.58 | 2019-2020 | |
| Allergan, INC. | $115.98 | 2020 | |
| Halozyme INC | $98.74 | 2019-2020 | |
| Alcon Vision LLC | $97.49 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $36.56 | 2019-2020 | |
| Shire North American Group INC | $27.33 | 2019 | |
| Novartis Pharmaceuticals Corporation | $27.17 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.84 | 2020 | |
| Biotissue Holdings INC. | $21.23 | 2020 | |
| Coopervision INC. | $20.82 | 2019 | |
| Horizon Therapeutics Plc | $15.69 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.